Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 2/20 | 0.43 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.43 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4518381 | 1.00 | PRKD3 (0.43) | PRKD3PRKD1PRKD2ESR1ESR2 | |
| SCHEMBL4518375 | 1.00 | PRKD3 (0.43) | PRKD3PRKD1PRKD2ESR1ESR2 | |
| SCHEMBL4516717 | 0.87 | ESR1 (0.37) | PRKD3PRKD1PRKD2ESR1ESR2 | |
| SCHEMBL4516699 | 0.87 | ESR1 (0.37) | PRKD3PRKD1PRKD2ESR1ESR2 | |
| SCHEMBL4516710 | 0.87 | ESR1 (0.37) | PRKD3PRKD1PRKD2ESR1ESR2 | |
| SCHEMBL4514171 | 0.85 | PRKD3 (0.45) | PRKD3PRKD1PRKD2 | |
| SCHEMBL4514167 | 0.85 | PRKD3 (0.45) | PRKD3PRKD1PRKD2 | |
| SCHEMBL4514159 | 0.85 | PRKD3 (0.45) | PRKD3PRKD1PRKD2 | |
| SCHEMBL14865911 | 0.81 | PRKD3 (0.41) | PRKD3PRKD1PRKD2ESR1ESR2 | |
| SCHEMBL4516698 | 0.80 | CDK9 (0.41) | PRKD3PRKD1PRKD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| WO-2007125331-A2 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | PKD2, PKD1, AADAT | PRKD3 9/4885PRKD1 49/4885PRKD2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.